Navigation Links
Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos

A NOVEL research-cum-manufacturing agreement between Chiron Corp, the US-based vaccine major, and an Indian company for the development of a potential AIDS vaccine to halt the spread of the deadly disease in the country is in an advanced stage of finalisation.

Two Hyderabad-based biotechnology/pharma companies -- Shanta Biotechnics and Biological E -- are reportedly the front-runners for the proposed project, which entails an upfront technology transfer fee of $30 million being sought by Chiron Corp, according to industry sources.

The Union Department of Biotechnology (DBT), which received the proposal from Chiron Corp, invited four Indian biotech/pharma companies for discussions towards January-end. These were Ranbaxy Research Laboratories, Serum Institute of India, Shanta Biotechnics and Biological E.

``We are closely examining the proposal made by Chiron Corp as part of our industry-academia initiatives and will take a decision on the Indian partner soon,'' the Secretary of DBT, Dr Manju Sharma, told Business Line.

The DBT expert group on vaccines is looking at the candidate vaccine against AIDS claimed and offered as technology transfer by Chiron Corp. The vaccine is said to be close to being subjected to human trials.

The Managing Director of Shanta Biotechnics (one of the favourites for the collaboration), Mr K. Varaprasada Reddy, confirmed that his company had detailed discussions with Chiron Corp. ``We are willing to take up the project if selected,'' he told Business Line.

Scientists of Chiron Corp including its Chairman had visited the facilities of Shanta Biotechnics during 2000. ``We also have the advantage of possessing recombinant DNA technology for producing vaccines,'' Mr Reddy said.

The collaboration with Chiron Corp would help in giving India a lead of couple of years in the realisation of a viable AIDS vaccine. The funds for carrying out the relevant research and developm ent, however, have to be raised. The vaccine had to be fine-tuned to be effective against the HIV variant, prevalent in India, Mr Reddy said.

Shanta Biotechnics was in the process of finalising its plans for a private placement to raise funds both for establishing an US FDA-approved research-cum-manufacturing facility and also to take up joint initiatives with pharma majors like the above, he said.

Various studies and forecasts made on AIDS in India warn of an epidemic with infection numbers being put at nearly 40 lakh at present. With the costs of the few available anti-AIDS drugs still very much beyond the affordability of the victims, a vaccine is being perceived as a welcome development.

DBT and the Union Ministry of Health have already started a vaccine development project under the Indo-US initiative on HIV/AIDS.


'"/>




Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Missing Protein In Cancer Development
3. Tomatoes Might Inhibit the Development Of Prostate Cancer
4. Pollution Found To Impair Lung Development
5. Treating Depression In Children Could Lead To Poor Bone Development
6. Developmental Origins of Polycystic Ovarian Syndrome
7. Sleep Not Critical For Early Brain Development Of Baby Dolphins
8. ‘Loud Noise’ Research may help in Development of Prosthetics for Eldery
9. Stop Watching TV: Toddler Development Affected
10. Vitamin Supplements During Pregnancy to Boost Fetal Development
11. Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: